表示向下
发表于 2025-3-30 09:40:21
Talimogene Laherparepvec (T-VEC)ffects are usually mild to moderate in severity, in contrast to isolated limb perfusion (ILP) and systemic treatments (e.g., molecular-targeted therapy and systemic checkpoint inhibitors), respectively. Real world use (so far, in small groups of patients) of T-VEC monotherapy has shown response rate
使满足
发表于 2025-3-30 13:17:35
Book 2021onal authors from expert melanoma centres in Europe, the book provides knowledge distilled from the diverse perspectives of the contributing authors (pathologists, translational scientists and clinicians). This book is of interest to medical oncologists, oncological surgeons, dermatologists and immu
宪法没有
发表于 2025-3-30 20:01:39
http://reply.papertrans.cn/67/6659/665855/665855_53.png
CHIP
发表于 2025-3-30 23:33:05
http://reply.papertrans.cn/67/6659/665855/665855_54.png